- $42.41m
- $42.17m
- 12
- 38
- 27
- 15
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -5698.65% | ||
| Return on Equity | -516.03% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | 1 | 9.3 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
IR-Med, Inc. is a development-stage medical device company. The Company is engaged in developing its technology through its subsidiary and is utilizing Infra-Red-light spectroscopy (IR) combined with artificial intelligence (AI) technology platform to develop non-invasive devices for various medical indications, by detecting and measuring various biomarkers and molecules in the blood and in human tissue in real-time. The Company has three principal medical devices in development. Its product under development, PressureSafe, is a handheld optical monitoring device that is being developed to support early detection of pressure injuries (PI) to the skin and underlying tissue. DiaSafe is a handheld optical monitoring device that is being developed to support early detection of DFUs in lower limb skin and underlying tissue. Nobiotics is an otoscope designed to support physicians with an immediate indication as to whether a mid-ear infection (otitis media) is of a bacterial origin.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- April 20th, 2007
- Public Since
- July 18th, 2001
- No. of Shareholders
- 719
- No. of Employees
- 6
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq- Shares in Issue
- 70,690,056
- Address
- C/O ABOUDI LEGAL GROUP PLLC, NEW YORK, 10151
- Web
- https://www.ir-medical.com/
- Phone
- +1 6467684285
- Auditors
- Somekh Chaikin KPMG.
Upcoming Events for IRME
Similar to IRME
Aamaxan Transport
Pink Sheets on Nasdaq
ACCUSTEM SCIENCES
Pink Sheets on Nasdaq
Acutus Medical
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
Advanced Biomedical Technologies
Pink Sheets on Nasdaq
FAQ
As of Today at 21:25 UTC, shares in IR-MED are trading at $0.60. This share price information is delayed by 15 minutes.
Shares in IR-MED last closed at $0.60 and the price had moved by -40% over the past 365 days. In terms of relative price strength the IR-MED share price has underperformed the S&P500 Index by -49.64% over the past year.
There is no consensus recommendation for this security.
IR-MED does not currently pay a dividend.
IR-MED does not currently pay a dividend.
IR-MED does not currently pay a dividend.
To buy shares in IR-MED you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.60, shares in IR-MED had a market capitalisation of $42.41m.
Here are the trading details for IR-MED:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: IRME
Based on an overall assessment of its quality, value and momentum IR-MED is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in IR-MED is $3.00. That is 400% above the last closing price of $0.60.
Analysts covering IR-MED currently have a consensus Earnings Per Share (EPS) forecast of -$0.05 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like IR-MED. Over the past six months, its share price has underperformed the S&P500 Index by -52.75%.
As of the last closing price of $0.60, shares in IR-MED were trading -42.74% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The IR-MED PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.60.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on IR-MED's directors